Klaria Pharma Holding AB (publ)
STO:KLAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (8.9), the stock would be worth kr0.33 (64% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 24.9 | kr0.91 |
0%
|
| 3-Year Average | 8.9 | kr0.33 |
-64%
|
| 5-Year Average | 10.3 | kr0.38 |
-59%
|
| Industry Average | 7.9 | kr0.29 |
-68%
|
| Country Average | 2.1 | kr0.08 |
-91%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
kr203.8m
|
/ |
Jan 2026
kr9m
|
= |
|
|
kr203.8m
|
/ |
Dec 2026
kr24.5m
|
= |
|
|
kr203.8m
|
/ |
Dec 2027
kr34.9m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
K
|
Klaria Pharma Holding AB (publ)
STO:KLAR
|
224.3m SEK | 24.9 | -5.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 13.2 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 6 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 5.2 | 27.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 5.2 | 19.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 4.7 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 108.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4.1 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 3.2 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 3.1 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 2.1 |
| 70th Percentile | 5.1 |
| Max | 15 188 |
Other Multiples
Klaria Pharma Holding AB (publ)
Glance View
Klaria Pharma Holding AB engages in the development and commercialization of pharmaceutical products for migraine and cancer-related pain. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-10-21. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The firm operates Klaria Pharma AB as a wholly owned subsidiary.
